PMID- 9435427
OWN - NLM
STAT- MEDLINE
DCOM- 19980209
LR  - 20171116
IS  - 0021-972X (Print)
IS  - 0021-972X (Linking)
VI  - 83
IP  - 1
DP  - 1998 Jan
TI  - Nicotinamide decreases cytokine-induced activation of orbital fibroblasts from 
      patients with thyroid-associated ophthalmopathy.
PG  - 121-4
AB  - We used flow cytometry to investigate the effects of nicotinamide, an inhibitor 
      of poly (ADP ribose) synthetase, on the cell-surface expression of 
      cytokine-induced human leukocyte antigen (HLA)-A,B,C antigen, HLA-DR antigen, 
      intercellular adhesion molecule 1, CD44, and Fas expression in cultured orbital 
      fibroblasts from patients with thyroid-associated ophthalmopathy. After two to 
      seven passages, cultured orbital fibroblasts were incubated for 3 days with 
      interferon gamma or tumor necrosis factor alpha in the presence of nicotinamide. 
      Nicotinamide inhibited the induction of both HLA-DR and intercellular adhesion 
      molecule 1 expression by cytokines on fibroblasts but did not interfere with 
      induction of HLA-A,B,C, or CD44 expression. Nicotinamide also inhibited the 
      proliferation of orbital fibroblasts, as assessed by a [3H]-thymidine 
      incorporation assay and cell counts. Nicotinamide also enhanced the expression of 
      the apoptosis-mediating protein Fas on fibroblasts. Our data suggest that 
      nicotinamide inhibits cytokine-induced activation of fibroblasts and thus may 
      decrease the autoimmune injury to the orbit in thyroid-associated ophthalmopathy.
FAU - Hiromatsu, Y
AU  - Hiromatsu Y
AD  - Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan.
FAU - Yang, D
AU  - Yang D
FAU - Miyake, I
AU  - Miyake I
FAU - Koga, M
AU  - Koga M
FAU - Kameo, J
AU  - Kameo J
FAU - Sato, M
AU  - Sato M
FAU - Inoue, Y
AU  - Inoue Y
FAU - Nonaka, K
AU  - Nonaka K
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (Cytokines)
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-B Antigens)
RN  - 0 (HLA-C Antigens)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Hyaluronan Receptors)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (fas Receptor)
RN  - 126547-89-5 (Intercellular Adhesion Molecule-1)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Adipose Tissue/*enzymology/pathology
MH  - Cell Division/drug effects
MH  - Cells, Cultured
MH  - Cytokines/*pharmacology
MH  - Fibroblasts/drug effects/immunology/pathology
MH  - Graves Disease/*immunology
MH  - HLA-A Antigens/biosynthesis
MH  - HLA-B Antigens/biosynthesis
MH  - HLA-C Antigens/biosynthesis
MH  - HLA-DR Antigens/*biosynthesis
MH  - Histocompatibility Antigens Class I/*biosynthesis
MH  - Humans
MH  - Hyaluronan Receptors/biosynthesis
MH  - Intercellular Adhesion Molecule-1/biosynthesis
MH  - Interferon-gamma/pharmacology
MH  - Niacinamide/*pharmacology
MH  - Orbit
MH  - Skin/drug effects/immunology
MH  - Tumor Necrosis Factor-alpha/pharmacology
MH  - fas Receptor/biosynthesis
EDAT- 1998/01/22 00:00
MHDA- 1998/01/22 00:01
CRDT- 1998/01/22 00:00
PHST- 1998/01/22 00:00 [pubmed]
PHST- 1998/01/22 00:01 [medline]
PHST- 1998/01/22 00:00 [entrez]
AID - 10.1210/jcem.83.1.4478 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 1998 Jan;83(1):121-4. doi: 10.1210/jcem.83.1.4478.